Protara Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Protara Therapeutics, Inc. (TARA) reported Proceeds from Sale and Maturity of Marketable Securities of $66.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-11
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $37.32M, a 832.98% increase year-over-year.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $29.14M, a 288.48% increase year-over-year.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $35.82M, a 59.22% increase year-over-year.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $17.91M.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $65.23M, a 34.23% increase from fiscal 2024.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $48.60M, a 25.62% decline from fiscal 2023.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $65.34M, a 11.46% increase from fiscal 2022.
- Protara Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $58.62M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $66.45M 10-Q · filed 2026-08-11 | $102.28M derived: sum of 3 quarters · filed 2026-08-11 | $120.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $29.14M 10-Q · filed 2026-05-13 | $64.96M derived: sum of 2 quarters · filed 2026-05-13 | $82.87M derived: sum of 3 quarters · filed 2026-05-13 | $86.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $35.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $53.73M derived: sum of 2 quarters · filed 2026-03-10 | $57.73M derived: sum of 3 quarters · filed 2026-08-11 | $65.23M 10-K · filed 2026-03-10 |
| 2025-09-30 | $17.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $21.91M derived: sum of 2 quarters · filed 2026-08-11 | $29.41M 10-Q · filed 2025-11-10 | $51.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $11.50M 10-Q · filed 2026-08-11 | $34.00M derived: sum of 3 quarters · filed 2026-08-11 | $34.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.50M 10-Q · filed 2026-05-13 | $30.00M derived: sum of 2 quarters · filed 2026-05-13 | $30.00M derived: sum of 3 quarters · filed 2026-05-13 | $33.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $22.50M derived: sum of 2 quarters · filed 2026-03-10 | $25.50M derived: sum of 3 quarters · filed 2026-03-10 | $48.60M 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.00M derived: sum of 2 quarters · filed 2025-11-10 | $26.10M 10-Q · filed 2025-11-10 | $40.62M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $26.10M 10-Q · filed 2025-08-11 | $40.62M derived: sum of 3 quarters · filed 2025-08-11 | $47.03M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $23.10M 10-Q · filed 2025-05-08 | $37.62M derived: sum of 2 quarters · filed 2025-05-08 | $44.03M derived: sum of 3 quarters · filed 2025-05-08 | $66.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $20.93M derived: sum of 2 quarters · filed 2025-03-05 | $43.29M derived: sum of 3 quarters · filed 2025-03-05 | $65.34M 10-K · filed 2025-03-05 |
| 2023-09-30 | $6.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $28.77M derived: sum of 2 quarters · filed 2024-11-12 | $50.82M 10-Q · filed 2024-11-12 | $61.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $22.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $44.41M 10-Q · filed 2024-08-06 | $55.19M derived: sum of 3 quarters · filed 2024-08-06 | $74.32M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $22.05M 10-Q · filed 2024-05-02 | $32.84M derived: sum of 2 quarters · filed 2024-05-02 | $51.97M derived: sum of 3 quarters · filed 2024-05-02 | |
| 2022-12-31 | $10.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $29.91M derived: sum of 2 quarters · filed 2024-03-13 | $58.62M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $19.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $47.84M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $28.71M 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |